Clever Culture Systems Limited (CC5) Earnings Call Transcripts

Clever Culture Systems Limited's Latest Earnings Call - Q3 FY2026

In the March quarter of FY '26, Clever Culture Systems Limited (CC5:AU) reported solid progress in its commercialization strategy, achieving 9 APAS instrument placements, consistent with FY '25. The company continues to rely heavily on AstraZeneca, which accounted for approximately 80% of sales in the previous year, but management is optimistic about diversifying its customer base with expectations to add at least 2 new top 20 pharmaceutical customers imminently. Financially, the company remains well-capitalized with $2 million in cash and projected cash inflows of at least $2.6 million over the next two quarters, largely from committed sales and R&D tax incentives.

Reported metrics

Guidance from management

Management expects to add at least 2 additional top 20 pharmaceutical customers in the next 2 months and anticipates larger rollouts in FY '27 as new customers validate the technology.

What management said

Thank you for standing by, and welcome to the Clever Culture Systems quarterly investor call. [Operator Instructions] On today's call is Brent Barnes, CEO and Managing Director; Rebecca Wilson, Chair of the Board; and Ray Ridge, the company's Chief Financial Officer. I will facilitate a question-and-answer session at the end of the presentation. An audio recording of this call will be made available on the company's ...

Thank you, Jack. I would like to remind those listening to this call that today's update may contain forward-looking statements, which do involve inherent risks and uncertainties. Those risks and uncertainties include those disclosed in our ASX documents, which we recommend that you review. There are reasonable grounds for any forward-looking statements made today. However, due to their inherent uncertainties, we rec...

What analysts pressed on

Analysts expressed concerns regarding the prolonged evaluation period with Pfizer and the potential impact of customer decision-making timelines on future sales. There were also questions about the implications of Thermo Fisher clearing its inventory on future orders and enthusiasm for the partnership.

Main topics on the call

• Diversification of Customer Base — Management emphasized the importance of expanding beyond AstraZeneca, stating, "we do expect to add at least 2 additional top 20 pharma customers in the next 2 months." This diversification is crucial for sustainable gro...
• Sales Performance — Clever Culture secured 3 new APAS Independence orders in the March quarter, bringing the total to 9 units for FY '26. The company is on track to meet its FY '25 result of 11 units, indicating steady sales performance.
• Financial Position — The company reported $2 million in cash at the end of the quarter and expects cash inflows of at least $2.6 million in the next two quarters. This solid financial position supports ongoing operations and growth initiativ...
• Validation of Technology — Clever Culture received independent validation of its technology, with AstraZeneca winning the Professor Wallhäußer award for its implementation of APAS. This recognition enhances the credibility of the product and could...

Read the full Clever Culture Systems Limited transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 20 Clever Culture Systems Limited earnings call transcripts on record, spanning April 29, 2020 to April 30, 2026. Based on this history, Clever Culture Systems Limited reports semi-annually. The most recent call on file is dated April 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CC5

Exchange

ASX

Country

AU

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

20

First call

April 29, 2020

Most recent

April 30, 2026

Reporting cadence

semi-annually